Andexanet alfa reverses blood thinning of rivaroxaban

Full results from a Phase III study examining Portola Pharmaceutical's developmental compound andexanet alfa found it rapidly and significantly reversed the anticoagulant effects of rivaroxaban (Xarelto). These results will be presented at the American College of Cardiology (ACC) meeting on March 16.

Full results from a Phase III study examining Portola Pharmaceutical's developmental compound andexanet alfa found it rapidly and significantly reversed the anticoagulant effects of rivaroxaban (Xarelto). These results will be presented at the American College of Cardiology (ACC) meeting on March 16. Paul Burton, MD, PhD, Vice President, Medical Affairs, Janssen, said: "Patients taking blood thinners are doing so to treat or help prevent life-threatening blood clots from forming in their body. If the need arises to stop this effect, andexanet alfa may add to current reversal strategies for Xarelto. Stopping treatment with Xarelto may allow for patients to return to near-normal levels of coagulation within 24 hours. In addition, the use of prothombin complex concentrate, or PCC, has been observed to partially reverse the anticoagulant or blood thinning activity of Xarelto in healthy people." In addition, new 24-month results from an ongoing, 5-year, observational study of people with nonvalvular atrial fibrillation taking rivaroxaban will be presented at ACC on March 15. Results showed the rates and patterns of major bleeding in routine clinical practice were generally consistent with those observed in Phase III clinical trials used to approve rivaroxaban for this indication.